VIROMETIX
Virometix is a privately held biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and chronic human diseases. In an increasingly global world there is a considerable medical need for vaccines to combat infectious as well as a number of chronic human diseases. Fast growing demands, health threats from newly arising complex viral and bacterial pathogens and increasingly stringent requirements for stability, safet... y and tolerability require new approaches to tackling current and future challenges. Rational molecular design, chemical synthesis and Virometix' proprietary Synthetic Virus-Like Particle platform technology allow for the rapid production and optimization of vaccine candidates with superior properties in terms of safety, efficacy and stability.
VIROMETIX
Industry:
Biotechnology Health Care Medical
Founded:
2009-01-01
Address:
Schlieren, Zurich, Switzerland
Country:
Switzerland
Website Url:
http://www.virometix.com
Total Employee:
11+
Status:
Closed
Contact:
+41 (0) 43 433 86 60
Email Addresses:
[email protected]
Total Funding:
13.71 M CHF
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro SPF Apple Mobile Web Clips Icon Google Font API Google Tag Manager WordPress Google Maps SSL By Default
Similar Organizations
Aerogen
Aerogen is a medical device and drug delivery company.
BioCentrum
BioCentrum is a privately-owned biotechnology service and product provider.
Calimmune
Calimmune is a clinical-stage gene therapy company.
Crioestaminal
Crioestaminal is a privately held biotechnology company that engages in preservation of stem cells to treat future ailments.
Cytovation
Cytovation AS is a privately-held biotech company, specialising .
Genis
Genis is a privately held biotechnology company located in Iceland.
Gubra
Gubra is a privately-held biotech company
Mucosis
Mucosis is a clinical stage Dutch biotechnology company developing mucosal vaccines.
Novellus
Novellus is a biotechnology company working to develop engineered cellular medicines.
Themis Bioscience
Themis Bioscience is a start-up biotechnology company.
Current Advisors List
Current Employees Featured
Investors List
Harry Welten
Harry Welten investment in Series A - Virometix
Venture Kick
Venture Kick investment in Grant - Virometix
Official Site Inspections
http://www.virometix.com Semrush global rank: 9.98 M Semrush visits lastest month: 286
- Host name: 104.21.4.27
- IP address: 104.21.4.27
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Virometix"
Home - Virometix AG
Virometix AG is a clinical stage biotech company pioneering a new class of synthetic vaccines to tackle infectious diseases and cancer. Our structure-based vaccines are designed to direct a precise, robust and sustained immune …See details»
About us - Virometix AG
Virometix AG is a privately held Swiss biotechnology company whose purpose is the discovery and development of fully synthetic vaccines to generate targeted and protective immune responses against infectious diseases and cancer.See details»
About us - Virometix AG
Interested in learning more about our company, our technology, or our pipeline? Please contact us here.See details»
Virometix AG – Swiss Biotech
Virometix AG is a privately held biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and chronic …See details»
Virometix - Crunchbase Company Profile & Funding
View contacts for Virometix to access new leads and connect with decision-makers. Virometix is a privately held biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and …See details»
Virometix AG - LinkedIn
Developing a new generation of vaccines and immunotherapeutic drugs | Virometix is a privately held Swiss biotechnology company developing a new generation of vaccines and immunotherapeutic...See details»
Virometix Company Profile 2024: Valuation, Funding & Investors
Developer of vaccines and immunotherapeutic drugs designed to prevent and treat infections and chronic human diseases.See details»
Virometix - VentureRadar
Virometix AG is a privately held biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and chronic …See details»
Virometix AG Company Profile | Schlieren, ZÜRICH, Switzerland ...
Find company research, competitor information, contact details & financial data for Virometix AG of Schlieren, ZÜRICH. Get the latest business insights from Dun & Bradstreet.See details»
Virometix Broadens Senior Leadership Team with Three Key …
Jan 7, 2021 · Virometix AG is a privately held Swiss biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of …See details»
Virometix - Products, Competitors, Financials, Employees, …
Investors of Virometix include University of Zurich and Venture Kick. Virometix is a clinical stage biotech company focused on developing synthetic vaccines for infectious diseases and …See details»
Virometix appoints Christina Ackermann as Chair and Tim
Oct 8, 2024 · Virometix AG is a privately held Swiss biotechnology company developing a new generation of fully synthetic vaccines to generate targeted and protective immune responses …See details»
Next-generation nanoparticle vaccine technology directed to scale …
May 27, 2022 · Virometix, a next-generation Swiss, is applying breakthrough synthetic virus-like particle (SVLP) and synthetic antigen mimetic technologies to neutralise viruses, bacteria and …See details»
Virometix Company Profile - Office Locations, Competitors, …
Virometix is a biotechnology company that develops vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and chronic human diseases. It specializes in …See details»
Newsroom - Virometix AG
Jul 9, 2020 · August 2022 – Virometix has obtained positive preclinical data with its serotype-independent, peptide-based vaccine candidate against S. pneumoniae, delivered by our …See details»
Virometix to kick off in-human studies of its first vaccine candidate
Mar 16, 2020 · The Belgian health authority, FAMHP, has approved Virometrix’s clinical trial application for the first-in-human phase 1 study of its respiratory syncytial virus (RSV) vaccine …See details»
Virometix Announces Publication of Key Non-Clinical Proof-of …
Jul 14, 2021 · Virometix AG is a privately held Swiss biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of …See details»
Virometix Broadens Senior Leadership Team with Three Key
Jan 7, 2021 · Virometix, a privately held Swiss biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of …See details»
Pneumococcal vaccine - Virometix - AdisInsight
Virometix, in collaboration with the University of Zurich and the Swiss Tropical and Public Health Institute, is developing a broad-spectrum next-generationSee details»